CASP3 and sarcoma: At 24 h after dulanermin administration, there was a statistically significant increase in circulating caspase 3/7 levels from CRC (median increase: 23%, P=0.04) and sarcoma patients (median increase: 19%, P=0.03) (Figure 3A and Table 2).